CNXU stock forecast, quote, news & analysis
Conexeu Sciences Inc is an early-stage medical technology company... Show more
Why Conexeu Sciences (CNXU) Stock Is Down -39% in the Last 30 Days
Key Takeaways
- CNXU has fallen roughly 39% over the last 30 days, sliding from a $3.77 close on October 12 to about $2.31 in the latest session.
- Conexeu Sciences is a pre-revenue regenerative medicine company developing collagen-based tissue scaffolds for medical aesthetics and tissue repair.
- The decline extends a steep downtrend since the company's direct listing on the Nasdaq Capital Market in May 2026.
- The company reported no revenue and a net loss of approximately $11.7 million for the nine months ended July 31, 2026, driven partly by non-cash stock-based compensation.
- Rising operating costs, recurring capital-raising needs, and an FDA 510(k) submission still in progress remain central considerations for investors.
- Get more detail on the ticker's Price Targets, Earnings, and Forecast on dedicated analysis pages.
- Explore Trending AI Robots to see how automated trading strategies are positioned across thousands of tickers.
Conexeu Sciences (CNXU) Company Overview and Market Position
Conexeu Sciences Inc. is an early-stage regenerative medicine company developing collagen-based regenerative tissue scaffold products intended for medical aesthetics and tissue repair applications. The business is pre-revenue and pre-commercial, with its activities centered on research and development, validation of its proprietary platform, and preparation of regulatory submissions, including a 510(k) filing with the U.S. Food and Drug Administration.
The company completed a direct listing on the Nasdaq Capital Market in May 2026, raising approximately $7.7 million in net financing proceeds during the period. Investors follow CNXU for its exposure to the regenerative medicine and medical aesthetics sector, though the stock carries the risk profile typical of a recently listed, pre-revenue developer that is still dependent on recurring capital raises.
Conexeu Sciences (CNXU) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CNXU has declined approximately 39%, moving from a closing price of $3.77 on October 12 to around $2.31 in the most recent session. The move has been characterized by persistent downward pressure and elevated intraday volatility rather than a single sharp gap.
The broader quarterly trend is even steeper. Since the start of September, when the stock closed near $5.87, CNXU has fallen roughly 60%, reflecting a sustained multi-month selloff that began shortly after its spring 2026 Nasdaq listing. The overall pattern is one of steadily declining prices with intermittent but short-lived rebounds.
What Drove CNXU Stock Price in the Last 30 Days
The recent decline appears rooted in CNXU's fundamental profile rather than a single isolated news event. As a pre-revenue company, Conexeu Sciences does not yet generate sales, and its quarterly filings have shown widening net losses tied to the costs of operating as a newly public company. For the nine months ended July 31, 2026, the company reported a net loss of approximately $11.7 million, with notable increases in business development, consulting, and personnel expenses.
A substantial portion of those consulting costs reflected non-cash, stock-based compensation issued to marketing and investor-relations vendors, valued at then-current Nasdaq trading prices. This combination of ongoing losses, share-based compensation, and an acknowledged need to raise additional capital has contributed to investor caution and dilution concerns, weighing on the stock over the trailing month.
What Drove CNXU Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of post-listing normalization and risk repricing. After its May 2026 direct listing, the company allocated significant resources to marketing, business development, and investor relations aimed at building trading visibility and supporting capital-raising efforts. While these initiatives are common for newly listed issuers, they increased operating losses without generating revenue in the near term.
Investors have also had to weigh the pre-commercial stage of the business. With no revenue, a product candidate still progressing toward an FDA 510(k) submission, and recurring financing needs, the market has gradually repriced the shares lower across the quarter, extending the downtrend seen in the 30-day window.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a platform that operates hundreds of bots across thousands of tickers. Only the top-performing and most relevant strategies are featured in this section, helping traders identify automated approaches that are currently standing out. The bots span a range of strategies, timeframes, and performance metrics, so users can evaluate options that align with their own trading style and objectives. Exploring the page offers a practical way to see how algorithmic trading is being applied across the market.
CNXU Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for CNXU will likely center on regulatory progress and capitalization. The timing and outcome of the company's planned FDA 510(k) submission represent a key milestone, as regulatory clearance would be a foundational step toward eventual commercialization. Investors will also monitor updates on clinical or validation data for the company's tissue scaffold platform.
Financing activity is another central watchpoint. Given the company's pre-revenue status and rising operating costs, future capital raises and their dilutive impact could influence share price. Broader market sentiment toward small-cap, pre-revenue medical-device and biotech issuers, along with any changes to the company's expense trajectory, will also shape the stock's direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CNXU's RSI Indicator is staying in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CNXU just turned positive on November 09, 2026. Looking at past instances where CNXU's MACD turned positive, the stock continued to rise in 1 of 2 cases over the following month. The odds of a continued upward trend are 50%.
Following a +9.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNXU advanced for three days, in 11 of 16 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNXU as a result. In 7 of 7 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNXU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CNXU entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.896) is normal, around the industry mean (3.498). P/E Ratio (-4.544) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CNXU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNXU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology